Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Ensysce Biosciences (ENSC) Equity Average (2020 - 2025)

Historic Equity Average for Ensysce Biosciences (ENSC) over the last 6 years, with Q3 2025 value amounting to $2.3 million.

  • Ensysce Biosciences' Equity Average fell 4731.09% to $2.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.3 million, marking a year-over-year decrease of 4731.09%. This contributed to the annual value of $1.5 million for FY2024, which is 16531.1% up from last year.
  • As of Q3 2025, Ensysce Biosciences' Equity Average stood at $2.3 million, which was down 4731.09% from $3.2 million recorded in Q2 2025.
  • In the past 5 years, Ensysce Biosciences' Equity Average ranged from a high of $5.3 million in Q4 2024 and a low of -$5.2 million during Q4 2022
  • For the 5-year period, Ensysce Biosciences' Equity Average averaged around $258805.3, with its median value being $416926.0 (2023).
  • Its Equity Average has fluctuated over the past 5 years, first tumbled by 41514.93% in 2021, then surged by 117320.34% in 2024.
  • Quarter analysis of 5 years shows Ensysce Biosciences' Equity Average stood at -$4.3 million in 2021, then dropped by 22.34% to -$5.2 million in 2022, then soared by 107.98% to $416926.0 in 2023, then skyrocketed by 1173.2% to $5.3 million in 2024, then crashed by 56.74% to $2.3 million in 2025.
  • Its last three reported values are $2.3 million in Q3 2025, $3.2 million for Q2 2025, and $3.4 million during Q1 2025.